Aris Global Selects invivodata as Preferred ePRO Partner

Aris Global Selects invivodata as Preferred ePRO Partner

STAMFORD, Conn. & PITTSBURGH, Pa. - (BUSINESS WIRE) - Aris Global, a leading provider of software solutions for the life sciences industry, today announced that invivodata, the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, has been selected as its preferred partner for ePRO solutions.

invivodata's ePRO solutions - DiaryPRO for field-based data collection and SitePRO for in-clinic based data collection - will provide complementary functionality to Aris Global's Total Clinical suite of integrated solutions, which includes agCapture for electronic data capture, ARISg for drug safety, agXchange and agClinical for clinical trial management. Total Clinical enables companies to enter data once and share seamlessly across their enterprise, driving down costs and delivering significant efficiencies. The Total Clinical suite is available on a hosted, managed platform and includes a full range of delivery and support services.

Aris Global's strategy is to partner with best-of-breed solution providers currently serving the growing ePRO market. invivodata's ePRO solutions, built on an integration of proven scientific and regulatory principles that meet the FDA's PRO Guidance, are consistent with Aris Global's high standards of customer service.

"We are very excited about our partnership with invivodata," said Dr. Sylva H. Collins, vice president, Total Clinical Solutions at Aris Global. "The use of invivodata's proven ePRO system brings scientific and regulatory credibility in capturing the patient's experience in a clinical trial."

"Aris Global's Total Clinical suite offers real value to clinical researchers," said Doug Engfer, president and CEO at invivodata. "We look forward to working with them and aligning our eClinical solutions to further help life science organizations meet regulatory guidelines, manage risk and improve operational efficiencies."

About Aris Global
Aris Global (www.arisglobal.com) is a leading provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and medical information. More than 300 life science organizations rely on the company's advanced solutions for maintaining regulatory compliance, managing and mitigating risk, improving operational efficiency and easily sharing information on a global basis. Aris Global has headquarters in Stamford, CT, USA and regional offices in the UK, France, Germany, India and Japan, offering sales, implementation and support services.

About invivodata
invivodata is the only fully integrated PRO Solutions Organization (PSO) delivering regulatory-proven strategic consulting and practical ePRO solutions to biopharmaceutical companies where patient-centered research is a priority. From consulting on scale selection and study design to direct data collection from patients using invivodata's ePRO solutions, and then assisting in regulatory filings and meetings, invivodata helps its customers strategically use patient reported data to support labeling claims and other clinical program objectives. And through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, effectively contributing to the harmonization of each function to minimize scientific and clinical risk while maximizing efficiencies. invivodata's solutions have been used in nearly 300 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for global drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information, visit www.invivodata.com.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."